Skip to content

Study · Animal study (in vivo) · rat · 1997

2 results

Different cardiovascular profiles of three melanocortins in conscious rats; evidence for antagonism between gamma 2-MSH and ACTH-(1-24).

Van Bergen P, Kleijne JA, De Wildt DJ, Versteeg DH

British journal of pharmacology1 Apr 1997Cited by 17 (Europe PMC)

PMID9113379 (opens in a new tab)PMCIDPMC1564623 (opens in a new tab)DOI10.1038/sj.bjp.0701065 (opens in a new tab)PepBankPUB-09113379
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, intravenous NDP-MSH at doses up to 1000 nmol/kg did not affect blood pressure.

    In plain wordsIn rats, NDP-MSH given into a vein did not change blood pressure.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeBlood pressure
    Study

    ratn: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    up to 1000 nmol/kg · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Despite the fact that NDP-MSH is a potent agonist of various melanocortin receptor subtypes, among which the melanocortin MC1 receptor, it did not affect blood pressure or heart rate, when administered i.v. in doses of up to 1000 nmol kg-1.
    1 context sentence
    Summary · context
    We investigated the effects of [Nle4,D-Phe7]alpha-melanocyte-stimulating hormone (NDP-MSH), adrenocorticotropin-(1-24) (ACTH-(1-24)) and gamma 2-MSH, three melanocortins with different agonist selectivity for the five cloned melanocortin receptors, on blood pressure and heart rate in conscious, free…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In conscious rats, intravenous NDP-MSH at doses up to 1000 nmol/kg did not affect heart rate.

    In plain wordsIn rats, NDP-MSH given into a vein did not change heart rate.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeHeart rate
    Study

    ratn: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    up to 1000 nmol/kg · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Despite the fact that NDP-MSH is a potent agonist of various melanocortin receptor subtypes, among which the melanocortin MC1 receptor, it did not affect blood pressure or heart rate, when administered i.v. in doses of up to 1000 nmol kg-1.
    1 context sentence
    Summary · context
    We investigated the effects of [Nle4,D-Phe7]alpha-melanocyte-stimulating hormone (NDP-MSH), adrenocorticotropin-(1-24) (ACTH-(1-24)) and gamma 2-MSH, three melanocortins with different agonist selectivity for the five cloned melanocortin receptors, on blood pressure and heart rate in conscious, free…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.